Not yet recruitingPhase NA

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

Comparison of the Effects of Semaglutide and Tirzepatide Treatments in Combination With Exercise in Obesity Management

Lead sponsor

Istanbul Galata University

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI 30-40

Primary endpoint

•Body fat-muscle ratios (Body composition)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07319975

Org study ID2025-GLP1-OBESITY

Timeline

Milestones

Study start2025-12-29estimated

Study first posted2026-01-06actual

Last update posted2026-01-06actual

Primary completion2026-10estimated (month precision)

Study completion2026-12estimated (month precision)

Assets

Investigational agents

Semaglutide Tirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age25 Years

Maximum age60 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Those between the ages of 25 and 60 years

•Those with a body mass index (BMI) between 30 and 40 kg/m2 according to the World Health Organization (WHO) classification

•Individuals who volunteered to participate in the study

Exclusion criteria

•Individuals with a BMI greater than 40 kg/m2 according to the WHO classification

•Individuals with a Charlson comorbidity index score of 3 or higher

•Uncontrolled arrhythmia, hypertension, heart failure, diabetes, and unstable angina pectoris

•Cooperation impairment, orthopedic, and neurological problems that may interfere with evaluation and treatment

•Individuals with a history of lower extremity injury or surgery in the last six months

•Diagnosed with diabetes and complications such as nephropathy, retinopathy, and neuropathy

•Individuals with concomitant chronic respiratory disease

•Individuals with acute infections

•Individuals with middle ear pathologies (such as tympanic membrane rupture, otitis media)

•Individuals with a history of spontaneous or trauma-related pneumothorax

•Smokers

•Pregnancy

•Individuals with a STOP-bang score of 3 or higher

•Individuals on a structured diet program for weight loss during the study period

•Individuals who have had endoscopic intervention and/or bariatric surgery within the last year

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Weight & body composition

Glycemic / diabetes

Heart failure

Cardiometabolic biomarkers

Weight & body composition

2 endpoints

Primary/protocol endpoint

Body fat-muscle ratios (Body composition)

Time frame:Three months

ratio, improvement

Secondary/protocol endpoint

Peripheral muscle strength

Time frame:Three months

change from baseline, improvement

componentsquadriceps muscle strength, hand grip strength

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Glucose profile

Time frame:Three months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Heart failure

1 endpoint

Secondary/protocol endpoint

Functional capacity

Time frame:Three months

6-minute walk distance

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint/low confidence

Lipid Profile

Time frame:Three months

descriptive, improvement

Other clinical outcomes

4 endpoints

Secondary/protocol endpoint

Pulmonary function

Time frame:Three months

descriptive

Secondary/protocol endpoint

Respiratory muscle strength

Time frame:Three months

descriptive

Secondary/protocol endpoint

Physical activity level

Time frame:Three months

descriptive

Secondary/protocol endpoint

Incremental load test (Respiratory Muscle Endurance)

Time frame:Three months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.